Enhertu (trastuzumab deruxtecan)

Numéro de dossier de l’AMC: 23411

État des négociations:

Négociation envisagée

Indication(s):

For the treatment of adult patients with unresectable or metastatic hormone receptor (HR)-positive, HER2-low (IHC 1+ or IHC 2+/ISH-) or HER2-ultralow (IHC 0 with membrane staining) breast cancer who have received at least one endocrine therapy in the metastatic setting and are not considered suitable for endocrine therapy as the next line of treatment.

Promoteur/fabricant:

AstraZeneca Canada Inc.

Numéro de projet de l’AMC:

PC0401-000

Lettre d’entente de l’APP:

Sans objet

Conclusion du processus de négociation:

Sans objet